Autophagy contributes to metabolic reprogramming and therapeutic resistance in pancreatic tumors
G Reyes-Castellanos, N Abdel Hadi, A Carrier - Cells, 2022 - mdpi.com
Metabolic reprogramming is a feature of cancers for which recent research has been
particularly active, providing numerous insights into the mechanisms involved. It occurs …
particularly active, providing numerous insights into the mechanisms involved. It occurs …
Pancreatic cancer, radiomics and artificial intelligence
L Marti-Bonmati, L Cerdá-Alberich… - The British Journal of …, 2022 - academic.oup.com
Patients with pancreatic ductal adenocarcinoma (PDAC) are generally classified into four
categories based on contrast-enhanced CT at diagnosis: resectable, borderline resectable …
categories based on contrast-enhanced CT at diagnosis: resectable, borderline resectable …
Ketogenic HMG‐CoA lyase and its product β‐hydroxybutyrate promote pancreatic cancer progression
Pancreatic ductal adenocarcinoma (PDA) tumor cells are deprived of oxygen and nutrients
and therefore must adapt their metabolism to ensure proliferation. In some physiological …
and therefore must adapt their metabolism to ensure proliferation. In some physiological …
Ultra-sensitive CTC-based liquid biopsy for pancreatic cancer enabled by large blood volume analysis
NH Stoecklein, G Fluegen, R Guglielmi, RPL Neves… - Molecular Cancer, 2023 - Springer
The limited sensitivity of circulating tumor cell (CTC) detection in pancreatic
adenocarcinoma (PDAC) stems from their extremely low concentration in the whole …
adenocarcinoma (PDAC) stems from their extremely low concentration in the whole …
hENT1 as a Predictive Biomarker in PDAC—Response
We would like to thank Boyd and colleagues for their thoughtful comments on our work
demonstrating hENT1 as a predictive biomarker for gemcitabine and nab-paclitaxel (GnP) in …
demonstrating hENT1 as a predictive biomarker for gemcitabine and nab-paclitaxel (GnP) in …
[HTML][HTML] Evaluation of the cytotoxic and immunomodulatory effects of sonodynamic therapy in human pancreatic cancer spheroids
F Foglietta, P Panzanelli, R Pizzo, M Giacone… - … of Photochemistry and …, 2024 - Elsevier
Sonodynamic therapy (SDT) exploits the energy generated by ultrasound (US) to activate
sound-sensitive drugs (sonosensitizers), leading to the generation of reactive oxygen …
sound-sensitive drugs (sonosensitizers), leading to the generation of reactive oxygen …
[HTML][HTML] Determinants of gemcitabine response in pancreatic cancer: are we there?
OM Fitzpatrick, GM O'Kane - Journal of Gastrointestinal Oncology, 2023 - ncbi.nlm.nih.gov
1Department of Medical Oncology, Trinity St. James's Cancer Institute, Dublin, Ireland;
2Princess Margaret Cancer Centre, Toronto, Canada Correspondence to: Grainne M …
2Princess Margaret Cancer Centre, Toronto, Canada Correspondence to: Grainne M …
Single-cell analysis of an engineered organoid-based model of pancreatic cancer identifies hypoxia as a contributing factor in the determination of transcriptional …
Pancreatic ductal adenocarcinoma (PDAC) is a high-mortality cancer characterized by its
aggressive, treatment-resistant phenotype and a complex tumour microenvironment (TME) …
aggressive, treatment-resistant phenotype and a complex tumour microenvironment (TME) …
Impact of Sarcopenia on Patients with Localized Pancreatic Ductal Adenocarcinoma Receiving FOLFIRINOX or Gemcitabine as Adjuvant Chemotherapy
Simple Summary Pancreas cancer will become the second deadliest cancer in 2030. One-
third of patients with pancreatic cancer are treated with surgery followed by intravenous …
third of patients with pancreatic cancer are treated with surgery followed by intravenous …
Inverted Y‐shaped technique for complex superior mesenteric/portal vein reconstruction in pancreatoduodenectomy for locally advanced pancreatic head ductal …
B Kaluba, N Kuriyama, T Ito… - Annals of …, 2023 - Wiley Online Library
Most pancreatoduodenectomy (PD) procedures for locally advanced pancreatic head
adenocarcinoma (PDAC) require superior mesenteric/portal vein (SMV/PV) axis resection …
adenocarcinoma (PDAC) require superior mesenteric/portal vein (SMV/PV) axis resection …
